PURPOSE: To investigate the effect of 17alpha-ethynylestradiol (EE)-induced cholestasis on the expression of organic cation transporters (Octs) in the liver and kidney, as well as the pharmacokinetics and pharmacodynamics of metformin in rats. METHODS: Octs mRNA and protein expression were determined. The pharmacokinetics and tissue uptake clearance of metformin were determined following iv administration (5 mg/kg). Uptake of metformin, glucagon-mediated glucose production, and AMP-activated protein kinase (AMPK) activation were measured in isolated hepatocytes. The effect of metformin (30 mg/kg) on blood glucose levels was tested using the iv glucose tolerance test (IVGTT). RESULTS: The mRNAs of hepatic Oct1, renal Oct1, and Oct2 were decreased by 71.1%, 37.6%, and 94.5%, respectively, by EE cholestasis. The hepatic Oct1 and renal Oct2 proteins were decreased by 30.6% and 60.2%, respectively. The systemic and renal clearance of metformin were decreased. The in vitro hepatocyte uptake of metformin was decreased by 86.4% for V (max). Suppression of glucagon-stimulated glucose production and stimulation of AMPK activation in hepatocytes by metformin were diminished. In addition, metformin did not demonstrate a glucose-lowering effect during IVGTT in EE cholestasis. CONCLUSION: The antidiabetic effect of metformin may be diminished in diabetic patients with EE cholestasis, due to impaired hepatic uptake of the drug via OCT1.
PURPOSE: To investigate the effect of 17alpha-ethynylestradiol (EE)-induced cholestasis on the expression of organic cation transporters (Octs) in the liver and kidney, as well as the pharmacokinetics and pharmacodynamics of metformin in rats. METHODS:Octs mRNA and protein expression were determined. The pharmacokinetics and tissue uptake clearance of metformin were determined following iv administration (5 mg/kg). Uptake of metformin, glucagon-mediated glucose production, and AMP-activated protein kinase (AMPK) activation were measured in isolated hepatocytes. The effect of metformin (30 mg/kg) on blood glucose levels was tested using the iv glucose tolerance test (IVGTT). RESULTS: The mRNAs of hepatic Oct1, renal Oct1, and Oct2 were decreased by 71.1%, 37.6%, and 94.5%, respectively, by EE cholestasis. The hepatic Oct1 and renal Oct2 proteins were decreased by 30.6% and 60.2%, respectively. The systemic and renal clearance of metformin were decreased. The in vitro hepatocyte uptake of metformin was decreased by 86.4% for V (max). Suppression of glucagon-stimulated glucose production and stimulation of AMPK activation in hepatocytes by metformin were diminished. In addition, metformin did not demonstrate a glucose-lowering effect during IVGTT in EE cholestasis. CONCLUSION: The antidiabetic effect of metformin may be diminished in diabeticpatients with EE cholestasis, due to impaired hepatic uptake of the drug via OCT1.
Authors: N R Koopen; S M Post; H Wolters; R Havinga; F Stellaard; R Boverhof; F Kuipers; H M Princen Journal: J Lipid Res Date: 1999-01 Impact factor: 5.922
Authors: Gerald U Denk; Carol J Soroka; Albert Mennone; Hermann Koepsell; Ulrich Beuers; James L Boyer Journal: Hepatology Date: 2004-05 Impact factor: 17.425
Authors: María L Ruiz; Silvina S M Villanueva; Marcelo G Luquita; Mary Vore; Aldo D Mottino; Viviana A Catania Journal: Drug Metab Dispos Date: 2006-03-22 Impact factor: 3.922
Authors: M Savander; A Ropponen; K Avela; N Weerasekera; B Cormand; M-L Hirvioja; S Riikonen; O Ylikorkala; A-E Lehesjoki; C Williamson; K Aittomäki Journal: Gut Date: 2003-07 Impact factor: 23.059
Authors: Rai Ajit K Srivastava; Stephen L Pinkosky; Sergey Filippov; Jeffrey C Hanselman; Clay T Cramer; Roger S Newton Journal: J Lipid Res Date: 2012-07-13 Impact factor: 5.922